How Much Does Mounjaro Cost? (2026 Pricing Guide)

Mounjaro List Price Breakdown

Mounjaro (tirzepatide injection) is manufactured by Eli Lilly and is FDA-approved for type 2 diabetes. It works on both GLP-1 and GIP receptors — a dual mechanism that clinical trials have shown produces greater weight loss and blood sugar improvement than GLP-1-only medications like semaglutide.

The wholesale acquisition cost (WAC) for Mounjaro is approximately $1,023 per month across all dose levels:

• Mounjaro 2.5mg (starting dose): $1,023/month
• Mounjaro 5mg: $1,023/month
• Mounjaro 7.5mg: $1,023/month
• Mounjaro 10mg: $1,023/month
• Mounjaro 12.5mg: $1,023/month
• Mounjaro 15mg (max dose): $1,023/month

Like Novo Nordisk with Wegovy, Eli Lilly uses flat pricing across all dose levels. However, Mounjaro's list price is approximately $326/month cheaper than Wegovy's $1,349 list price, and Lilly has been far more aggressive with discount programs.

Eli Lilly Savings Card

Eli Lilly offers one of the most generous manufacturer savings programs in the GLP-1 space. The Mounjaro Savings Card is available for patients with commercial insurance:

• Copay reduction: Pay as little as $25 per month for Mounjaro
• Maximum savings: Up to $573 off per 28-day supply
• Duration: Valid for up to 24 months from activation
• Eligibility: Must have commercial (private) insurance; cannot be used with Medicare, Medicaid, or other government insurance

The savings card works by covering the gap between what your insurance pays and the $25 copay. If your insurance does not cover Mounjaro at all, the savings card alone will not bring the price down to $25 — it has a maximum monthly savings cap.

Important:If your insurance covers Mounjaro with a copay under $573, the savings card will likely bring your out-of-pocket cost to $25/month. If your insurance does not cover Mounjaro, the savings card reduces the price to approximately $450–$550/month instead of the full $1,023.

Zepbound: Same Drug, Weight Loss Label

Zepbound is the same molecule as Mounjaro (tirzepatide) but carries an FDA-approved indication for chronic weight management. Lilly sells them as separate products with different pricing and access programs:

• Zepbound list price: ~$1,060/month
• LillyDirect self-pay price: $349/month for single-dose vials
• Zepbound Savings Card: As low as $25/month with commercial insurance

The LillyDirect self-pay program at $349/month is the standout offering. This is available to anyone without insurance coverage for Zepbound and includes the medication delivered directly to your door. No insurance required, no income verification.

For patients primarily seeking weight loss, Zepbound through LillyDirect is often more affordable than Mounjaro at list price. If you have a diabetes diagnosis, Mounjaro with the savings card may be cheaper if your insurance covers it.

Mounjaro with Insurance

Insurance coverage for Mounjaro is generally better than for Wegovy because Mounjaro's primary indication is type 2 diabetes, which insurers are more willing to cover than obesity. However, coverage varies dramatically:

• With commercial insurance + savings card: As low as $25/month
• With insurance, no savings card: $50–$300/month typical copay
• Prior authorization: Almost always required; typically need documented A1C levels and failed metformin therapy
• Step therapy: Many plans require trying metformin, sulfonylurea, or SGLT2 inhibitor first
• Off-label for weight loss: Most commercial plans will not cover Mounjaro prescribed off-label for obesity without a diabetes diagnosis

If your insurer denies Mounjaro, ask your prescriber to check if Zepbound is covered under the plan's obesity benefit instead. Some plans cover Zepbound for weight loss but not Mounjaro off-label — even though they are the same drug.

Compounded Tirzepatide

Compounded tirzepatide remains more widely available than compounded semaglutide because the FDA has not yet declared the tirzepatide shortage officially over (as of March 2026). This means compounding pharmacies can still legally produce tirzepatide copies under the FDA's 503A and 503B exemptions.

• Typical price range: $200–$500/month
• Available from: Compounding pharmacies and some telehealth platforms
• FDA-approved: No — compounded versions are not FDA-approved
• Quality concerns: Variable potency, sterility, and purity; no brand-equivalent quality controls

While compounded tirzepatide is currently legal, this could change at any time if the FDA declares the shortage resolved. Patients using compounded tirzepatide should have a backup plan (such as LillyDirect at $349/month) in case compounding access is restricted.

Read our compounded vs brand comparison for a detailed safety and efficacy analysis.

No Oral Version Yet

Unlike semaglutide, which now has an oral tablet form (Oral Wegovy), there is no oral tirzepatide available as of March 2026. Eli Lilly is conducting clinical trials for an oral formulation of tirzepatide, but it is not expected to reach the market before 2028.

For patients who prefer to avoid injections, the main alternatives are:

• Oral Wegovy (semaglutide tablet): $149/month at lowest dose, FDA-approved
• Oral semaglutide (Rybelsus): FDA-approved for diabetes; lower dose than Oral Wegovy

However, if you want the dual GLP-1/GIP mechanism of tirzepatide, the injectable form is currently the only option. Many patients find that the once-weekly injection is less burdensome than a daily tablet that must be taken on an empty stomach.